Deeptech Investors

What are Deeptech investors, and what do they look for?

Deeptech investors are underwriting science risk rather than market risk, and that inversion changes every part of the conversation. In most venture categories the technology works and the question is whether anyone will buy it. Here the demand is often obvious and the question is whether the thing can be built at all, at cost, within a decade. Investors who are good at this are comfortable saying they do not know if the physics will cooperate, and pricing accordingly. The first thing they assess is whether there is genuine technical differentiation or merely technical complexity. Difficulty is not a moat. What matters is whether the difficulty produces an advantage a competitor cannot reach, ideally protected by patents, accumulated know-how or a manufacturing process that took years to tune. Second is the team's proximity to the science. Deeptech companies that spin out of research groups carry an advantage that is hard to acquire later: the founders have already spent years on the hard part. Investors will ask who actually holds the knowledge, and whether the institution or the company owns the intellectual property. Third is the path from laboratory to product, expressed in specific stages rather than in ambition. Investors want to see that you know which step is genuinely uncertain, what it costs to retire that uncertainty, and what the company is worth if it works. A founder who cannot name their riskiest assumption has usually not looked hard enough.

Why Deeptech is attracting investor interest

Two shifts pushed deeptech from a niche allocation into a mainstream one. The first is that several long-promised fields started producing things that work outside a laboratory: machine learning at useful accuracy, gene editing with clinical results, photonics and quantum devices moving from physics departments into products. Investors who had written these off as perpetually ten years away had to revise. The second is strategic. European governments and the EU concluded that dependence on foreign suppliers for semiconductors, batteries, pharmaceuticals and defence technology was a vulnerability rather than an efficiency. That conclusion came with money, through national programmes, EU instruments and procurement commitments, which materially improves the funding environment for exactly the companies private capital finds hardest to back alone. There is also a scarcity argument that appeals to funds directly. Software has low barriers to entry, which means competition and compressed returns. A company built on a decade of materials science has few credible competitors, and an investor who gets in early holds a position nobody can easily replicate by spending money faster. Europe's particular strength helps. The continent's research base is genuinely world class, and the historical weakness was commercialisation rather than science. A generation of technology transfer offices, university funds and specialist investors has narrowed that gap, so the raw material is now more reliably reachable by capital than it was.

Which funding stages Deeptech investors are active at

Deeptech stage structure is longer than venture norms and the milestones are technical rather than commercial. Pre-seed frequently means university spin-out capital: technology transfer offices, university-affiliated funds and specialist pre-seed investors funding the transition from a research result to a company. Intellectual property assignment and founder equity are negotiated here, and getting those terms wrong creates problems that persist for a decade. Seed funds the first serious attempt at reduction to practice outside the laboratory. Investors are buying a specific experiment, and rounds are sized to complete it with margin. Series A is where deeptech diverges most from software. Revenue is often still absent, so the round is justified by technical milestones achieved and by evidence of pull from an industrial partner. A signed development agreement with a large corporate is frequently worth more in this conversation than early revenue would be. Series B onwards funds scale-up, which for anything physical means manufacturing, and manufacturing means capital of a different magnitude and character. This is where blended stacks become normal: equity alongside public loans, strategic corporate investment and eventually asset finance. Growth and late-stage deeptech in Europe leans heavily on public institutions, sovereign vehicles and corporate strategics, with American and Asian funds increasingly present. Founders should map that landscape early, because the investors who fund the scale-up phase are rarely the ones who funded the science.

Typical check and round sizes in Deeptech

Quoting a typical figure would be misleading because deeptech spans companies whose capital needs differ by a factor of a hundred, from a software-adjacent algorithm business to a company that must build a fabrication facility. The more useful discipline is to size rounds against technical milestones and to be explicit about which uncertainty each round retires. Investors in this sector think in terms of risk removed per unit of capital, and a founder who presents the raise that way is speaking their language. A round that funds eighteen months of general operations without a named technical outcome is difficult to underwrite at any size. Add contingency deliberately rather than optimistically. Deeptech schedules slip because experiments fail, equipment lead times are long and specialised suppliers are scarce. Experienced investors apply their own multiplier to your timeline, and the way to avoid being repriced is to have applied it yourself. Non-dilutive funding matters more here than in almost any other category. European grant programmes, national research funding and EU instruments are substantial, and they are designed for precisely this stage. Companies that combine them with equity reach the same technical position having given away considerably less of the company, and investors treat successful grant applications as independent technical validation. For real benchmarks, compare against recent European rounds at your technology readiness level in your specific field rather than against deeptech aggregates, which blend fundamentally different capital profiles.

Types of investors active in Deeptech

What Deeptech investors look for in diligence

Deeptech diligence brings in outside technical expertise as a matter of course, so expect people who genuinely understand your field to read your material sceptically. Intellectual property is examined first and hardest. Who owns what, whether assignment from the university is complete and unconditional, what the licence terms actually permit, whether freedom to operate has been assessed, and whether the patents cover the commercial product or only the original research. Unresolved intellectual property is the most common reason a promising spin-out cannot raise. Technical validation follows. Investors want to know what has been demonstrated, under what conditions, how many times, and by whom. Independent replication carries disproportionate weight. So does a clear statement of what has not yet been shown, which experienced investors read as a sign of rigour rather than weakness. Scale-up feasibility gets assessed separately from the science. Many deeptech results work at gram scale and fail at tonne scale for reasons that were predictable. Investors will ask what changes with volume, which inputs become constraints, and whether the process tolerates industrial-grade materials rather than laboratory-grade ones. Team composition matters more than in software. Investors look for whether the company can execute beyond the research, which usually means asking who runs manufacturing, regulatory affairs or commercial development, and whether the academic founders intend to stay. Finally, capital path. Investors will ask how much total capital reaches commercial production and whether a credible route to it exists, because funding a company into a gap it cannot cross helps nobody.

How to build a fundraising strategy as a Deeptech startup

Frame the raise as buying down a specific technical risk. Deeptech investors are used to pre-revenue companies and are unbothered by the absence of customers; what they cannot underwrite is a vague plan. Naming the experiment, its cost, its timeline and what the company is worth if it succeeds converts an unbounded bet into a bounded one. Resolve intellectual property before you start raising. Incomplete assignment from a university, ambiguous licence terms or unresolved inventor claims will stop a process cold, and fixing them mid-diligence takes months. Investors read a clean intellectual property position as evidence of general competence. Pursue public funding as a parallel, staffed workstream. European deeptech grant and soft loan programmes are large enough to change your dilution outcome materially, and they operate on cycles that punish late starts. A successful competitive grant also functions as third-party technical validation. Get an industrial partner engaged early, even at a small scale. A joint development agreement, a paid pilot or a supply commitment from a credible corporate does more to de-risk your company in an investor's eyes than any additional laboratory result. Build the commercial half of the team before investors ask. Academic founding teams are frequently strong on science and thin on manufacturing, regulation and sales, and the gap is visible immediately. Naming the hire you intend to make, and having a candidate in mind, closes it cheaply. Plan the whole capital path rather than the next round. Show that you know what reaching production costs in total and where each tranche comes from, because an investor's real fear is funding you into a gap nobody will bridge.

Common mistakes founders make raising Deeptech capital

Presenting technical complexity as though it were a competitive advantage is the most common error. Investors ask what a well-funded competitor would have to do to catch up, and difficulty alone rarely produces a satisfying answer. The moat has to be something durable: process know-how, patents that cover the product, or data and materials that took years to accumulate. Leaving intellectual property unresolved is the most damaging. Founders assume the university relationship will be sorted later, and later arrives during diligence, at which point the leverage has shifted and the timeline has doubled. Underestimating scale-up is the classic deeptech failure. A result that works reliably in a laboratory frequently does not survive contact with industrial inputs, continuous operation or economic yield requirements. Companies that treat scale-up as an engineering formality rather than a research problem in its own right tend to discover the difference expensively. Raising against optimistic timelines produces a predictable sequence: milestone missed, bridge round from weakness, terms that damage the founding team. Building contingency into the original plan costs dilution once; missing a milestone costs more. Staying academic too long is a quieter failure. Publishing, conference presence and further research feel like progress but do not answer the commercial questions, and a company still optimising for papers three years in signals where its priorities sit. Finally, ignoring the capital landscape beyond the current round. Deeptech founders who have not worked out who funds their scale-up phase, and what those investors require, frequently discover at Series B that they have built something no available investor is structured to fund.

How Deeptech investment differs across Europe

The UK has an exceptional research base and the most developed spin-out ecosystem in Europe, with established university funds and a deep specialist investor community around Oxford, Cambridge and London. The recurring criticism is that scale-up capital remains thinner than the science pipeline warrants, so companies frequently raise later rounds internationally. Germany combines strong applied research institutions with an industrial base that can act as customer, partner and manufacturer. The applied research network in particular gives founders access to pilot facilities that would otherwise be unaffordable, and German industrial corporates are among the most active deeptech strategics in Europe. France has the most deliberate state-led deeptech strategy on the continent, with substantial public funding, a strong engineering and mathematics pipeline, and public co-investment as a normal feature rather than an exception. Public money is available at a scale that changes what is buildable. Switzerland's research institutions produce a disproportionate number of high-quality spin-outs relative to population, with strong local funding at early stages and considerable private wealth willing to hold long positions. The Nordics are strong in materials, industrial technology and quantum, with patient capital and close relationships between universities and industry. The Netherlands has genuine depth in photonics and semiconductor equipment, anchored by a supply chain that exists almost nowhere else, which makes it unusually attractive for hardware companies in adjacent fields. Central and Eastern Europe has strong technical universities and lower costs, producing capable teams that typically raise their later rounds in Western Europe or the US.